Zim Laboratories DuPont analysis

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
0.73×0.71×0.68×0.73×0.69×
0.66×0.82×0.76×0.93×1.02×
1.9%2.7%6.2%6.9%8.7%
0.74×0.74×0.83×0.93×1.17×
1.82×1.82×1.87×1.87×1.70×
1.3%2.1%5.0%8.2%12.2%
2.1%2.1%5.0%7.9%12.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ZIMLAB₹136.54

Zim Laboratories Limited

· Pharma & Health
₹ CrorePeersANUHPHRVALIANTLABAHCLALBERTDAVDWANBURYHALEOSLABSBAJAJHCARETHEMISMEDMcap ₹730 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.690.730.680.710.73
Interest Burden (Pretax/EBIT) ×1.020.930.760.820.66
EBIT Margin %8.666.916.232.681.94
Asset Turnover ×1.170.930.830.740.74
Financial Leverage (Assets/Equity) ×1.701.871.871.821.82
ROE (5-step product, year-end total equity) %12.238.174.992.101.26
ROE (owners' profit / average owners' equity) %12.207.864.962.132.13
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.